Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test

  • Roche Holdings AG RHHBY has launched the Elecsys HCV Duo immunoassay, the first available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or serum sample. 
  • The test can detect the early stage of infection, when the patient is recovering from the virus or showing signs of a chronic infection that may lead to other diseases, such as liver cancer.
  • Also Read: Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet.
  • The Elecsys HCV Duo assay enables a significantly earlier diagnosis of active hepatitis C virus infection than antibody-only assays by utilizing the dual detection of HCV core antigen and antibodies to HCV.
  • In 2019, 58 million people in the world were living with chronic hepatitis C infection, but only 21% were aware of it, according to World Health Organization data. The disease can lead to death from conditions including cirrhosis and liver failure.
  • Price Action: RHHBY shares closed higher by 2.49% at $42.46 on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!